Sanofi scraps development of amcenestrant breast cancer treatmentSanofi scraps development of amcenestrant breast cancer treatment
French healthcare company Sanofi said it would end the development programme of amcenestrant, an oestrogen receptor degrader aimed at treating breast cancer.The move puts more pressure on Sanofi to revive